Theranostics is a groundbreaking topic that's reshaping how we diagnose and treat cancer. It's a cutting-edge approach in cancer care, combining diagnosing and treating cancer using the same molecular tools. Theranostics has the spotlight because it's delivering on a promise we've been chasing for years in cancer care, truly personalized targeted treatment with fewer side effects than traditional options.

Guests:

Lindsay Williams, MBA, CNMT, R.T.(N)(CT)(ARRT)

Pharmacy Sourcing Portfolio Executive

Vizient

Setu Shah, MPH

Sr. Associate, Intelligence

Sg2

Janna Laton, MBA, CNMT, NMTCB(CT), R.T.(R)(N)(MR)(ARRT)

Independent Contributor and SME

Host:

Adam Fairbourn, MBA, CNMT

Senior Director, Contract Services

Vizient, Capital Equipment Solutions

Show Notes:

[00:45] Defining Theranostics and why it’s getting attention

[02:10] “See what you treat and treat what you see” captures the power of Theranostics

[03:10] Why neuroendocrine tumors and prostate cancer are particularly well suited for this approach

[03:50] Prostate specific membrane antigen or PSMA targeted imaging and treatment work and results

[05:28] How Theranostics compares with more traditional cancer treatments in terms of precision and side effects

Links | Resources:

Vizient article - https://www.vizientinc.com/insights/diagnostic-imaging

Sg2 Perspectives Podcast: Transforming Cancer Care Delivery

Sg2 Perspectives Podcast: Cell and Gene Therapy in Practice

Subscribe Today!

Apple Podcasts

Spotify

YouTube

RSS Feed